SUNDAY, SEPTEMBER 25, 2016

Phase two study results for meningococcal B vaccine

Two Pfizer, Inc., studies released on Friday found that its bivalent rLP2086 recombinant vaccine candidate for meningococcal disease was able to generate bactericidal responses.

The vaccine attempts to combat disease caused by Neisseria meningitidis serogroup B in 10 to 25 year olds. The bactericidal responses that were gauged are a measure of practical immune response after a series of two or three doses.

"Disease caused by meningococcus serogroup B is serious and unpredictable," Emilio Emini, the senior vice president of vaccine research and development for Pfizer, said. "The disease is difficult to recognize early and progresses rapidly, making preventive vaccination especially important."

There are over 500,000 cases of meningococcal disease each year as a result of Neisseria meningitidis. Although antibiotic treatment is oftentimes available, 10 to 15 percent of patients die every year and 11 to 19 percent suffer long-term disabilities.

"We are encouraged by the safety and tolerability data for our investigational vaccine candidate, bivalent rLP2086, and its potential to help prevent this devastating disease," Emini said. "We look forward to continuing the development of this critically-needed vaccine and working with regulatory authorities to make it available to adolescents and young adults."